Dexcom reports Q2 2026 revenue grew 13%
Operating income rose 590 basis points to 24.3% of revenue, and GAAP net income increased to $249.1 million.
See the latest news and media coverage for Dexcom. We track all announcements, press releases, and industry mentions in real time, all in one place.
Manufacturer of continuous glucose monitoring systems
dexcom.comLast updated
In short: Dexcom reported strong financial growth, expanded its product portfolio with the G8 and Stelo CGM, and faced activist investor pressure.
Operating income rose 590 basis points to 24.3% of revenue, and GAAP net income increased to $249.1 million.
The program aims to evaluate AI-powered glucose health and real-world evidence for earlier intervention in prediabetes and Type 2 diabetes.
The system is the longest-lasting and most accurate CGM authorized by Health Canada, offering 15.5 days of real-time glucose readings.
The release is after market close on July 30, 2026, with a conference call at 4:30 p.m. ET.
DexCom's fair value estimate has shifted from US$85.24 to US$91.64, marking a moderate uplift in the price target range currently referenced for the stock. This...
The Nasdaq rose 1.00%, while IES Holdings surged 30.27% and Amazon jumped 15.32%.
In late July 2026, DexCom reported second-quarter results showing higher sales and earnings than a year earlier and raised its full-year 2026 revenue outlook to...
Following the release of its Q2 results on 30 July, Dexcom's company's shares on the Nasdaq rose over 8% to $81.04 at market open on...
Track Dexcom and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Dexcom and other trending companies.